SILO: Silo Pharma, Inc. Stock

by  •  • Comments Off on SILO: Silo Pharma, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 5.87
Enterprise Value ($M) 1.01
Book Value ($M) 6.78
Book Value / Share 1.51
Price / Book 0.87
NCAV ($M) 6.48
NCAV / Share 1.44
Price / NCAV 0.91

Profitability (mra)
Return on Invested Capital (ROIC) -0.56
Return on Assets (ROA) -0.49
Return on Equity (ROE) -0.61

Liquidity (mrq)
Quick Ratio 7.91
Current Ratio 7.91

Balance Sheet (mrq) ($M)
Current Assets 8.26
Assets 8.57
Liabilities 1.78
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G/A Renaissance Technologies Llc 0.84
07-26 13G Intracoastal Capital, Llc 4.99 21.82

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT UND
2024-08-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT UNDER SE
2024-05-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT UNDER S
2024-03-25 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT PURSU

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-07 3,237 23,172 13.97
2025-03-06 49,674 76,345 65.07
2025-03-05 5,556 36,947 15.04
2025-03-04 11,671 42,259 27.62

(click for more detail)

Similar Companies
SCLX – Scilex Holding Company SGMO – Sangamo Therapeutics, Inc.
SHPH – Shuttle Pharmaceuticals Holdings, Inc. SLGL – Sol-Gel Technologies Ltd.
SLRX – Salarius Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io